As myeloproliferative neoplasms (MPNs) are a rare form of blood cancer, patients may not be aware of its effects. How do MPNs affect a patient’s quality of life, and what do your patients need to know?
Researchers sought to determine whether glofitamab monotherapy would have high preliminary response rates in patients with R/R non-Hodgkin lymphoma.
Researchers sought to determine whether loncastuximab tesirine would have durable responses in heavily pretreated patients with R/R DLBCL.
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Response and survival outcomes were similar with rituximab biosimilars and the originator.
Researchers seek to characterize adherence trajectories, determine how side effects or financial status influence adherence, assess how adherence effects clinical outcomes, and explore unique patient perspectives.
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
The approval was based on data from the open-label, multi-cohort phase 2 UNITY-NHL Trial.
